Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

All Drugs and Chemicals

Immunomodulating Agents

patients treated by Belantamab Mafodotin with a refractory multiple myeloma and an ophthalmologic follow-up between January 2020 and February 2022 will be included.

Data will be collected for patients coming from multiple French centers which followed patients treated by Belantamab Mafodotin between January 2020 and February 2022. They will be obtained by contacting centers through an email sent with a secure mail address.

The collected data are : sex, age, date of first immunotherapy cycle, dose, date of first consultation, objective refraction in spheric equivalent, keratometry, visual acuity, microcyst-like epithelial changes (MECs), location and density, corneal toxicity grade and complementary exams (topography, in vivo confocal microscopy).

Collection of datas

Marie Caroline TRONE, MD

Belantamab Mafodotin is the first antibody conjugate targeting B-cell maturation antigen (BCMA) in relapsed or refractory multiple myeloma (RRMM). It is used in multiple myeloma refractory to an immunomodulatory drug or proteasome inhibitor and refractory and/or intolerant to an anti-CD38 monoclonal antibody.

It has been found that the immunotherapy causes corneal side effects, Microcyst-like Epithelial Changes (MECs). They are round-shaped corneal inclusions that migrate from the peripheral cornea to the center, causing blurry vision, dryness and refractive shifts depending on their location and density.

This study aims at analysing the refractive shifts caused by Microcyst-like Epithelial Changes (MECs) and whether it can be used to monitor patients and facilitate their follow up.

Constitution of a French multicenter cohort.

Corneal Toxicity in Patients Treated by Belantamab Mafodotin

Corneal Toxicity in Patients Treated by Belantamab Mafodotin : How to Improve and Facilitate Patients Follow-up Using Refractive Shift ?

This scale is defined by 4 values : G1, G2, G3 and G4 (the best value is G1)

The severity grade of microcyst-like epithelial changes (MECs) is rated using the Keratopathy and Visual Acuity (KVA) scale after slit lamp examination.

The aim is to show a correlation between refractive shift and severity grade of microcyst-like epithelial changes (MECs)

The refraction is measured in spheric equivalent (SEQ) with an automated refractometer

The aim is to show a correlation between refractive shift and severity grade of microcyst-like epithelial changes (MECs)

The score is from 10/10 (best visual acuity) to 1/10 (worth visual acuity) Correlation between visual acuity and severity grade of microcyst-like epithelial changes (MECs)

Keratometry is measured in diopter using an autorefractometer or a topograph. This device measures the curvature of the anterior corneal surface based on the power of a reflecting surface. It does this by measuring the size of an image reflected from 2 paracentral points and utilizes doubling prisms to stabilize the image enabling more accurate focusing.

Correlation between keratometry and severity grade of microcyst-like epithelial changes (MECs)

Epithelial pachymetry is measured in micrometer (µm) using a topograph

Correlation between epithelial pachymetry and severity grade of microcyst-like epithelial changes (MECs)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Corneal Toxicity in Patients Treated by Belantamab Mafodotin	NCT05887206	Myeloma Multipl...	Collection of d...	18 Years -	Centre Hospitalier Universitaire de Saint Etienne
Corneal Toxicity in Patients Treated by Belantamab Mafodotin	NCT05887206	Myeloma Multipl...	Collection of d...	18 Years -	Centre Hospitalier Universitaire de Saint Etienne

Spots Global Cancer Trial Database for refractive shift